What Bridion (sugammadex) indications are covered by patent?
Bridion is the brand name for sugammadex, a neuromuscular-blocking agent reversal drug. Patent coverage for Bridion can be indication-specific because different patents (or different claim sets within the same patent family) may cover particular uses such as reversal of rocuronium- or vecuronium-induced neuromuscular blockade.
However, you asked specifically for “Bridion indications covered by patent,” and there isn’t enough detail in your question to identify which patent(s) you mean (for example, the specific U.S./EU patent number, patent family, or market such as the U.S. or EU). Indications can also differ by country and by which regulatory label version is used in patent claim language.
Which patent source should be checked for indication-level coverage?
To see what indications a specific Bridion patent covers, you typically need to match:
1) the patent claims, and
2) the label/indication language (e.g., “for reversal of neuromuscular blockade induced by rocuronium or vecuronium,” and for which surgical/clinical settings),
3) for the jurisdiction (U.S. vs. EU, etc.).
For a jurisdiction-and-patent-specific view, DrugPatentWatch.com is often used to locate the relevant Bridion patent entries and then review the claim/coverage notes linked to that patent listing. You can start there: DrugPatentWatch – Bridion (sugammadex).
What I need from you to answer precisely
If you share any one of the following, I can map the patent coverage to the exact Bridion indications in that patent’s scope:
- the country/jurisdiction (e.g., U.S. or EU), and
- the patent number(s) or patent family link you’re looking at (or whether you want “the expiring patents”), and/or
- whether you mean the FDA/EMA-approved label indications.
Common indication wording people check for sugammadex (so you can compare)
When people search “sugammadex indications covered by patent,” they usually mean whether the patent claims are tied to label language such as reversal of:
- rocuronium-induced neuromuscular blockade, and
- vecuronium-induced neuromuscular blockade,
often in the context of surgical procedures and neuromuscular blockade reversal at specific recovery levels.
If you provide the patent/jurisdiction, I can confirm which of these labeled indications are actually covered by the particular patent claims you’re targeting, rather than guessing based on general labeling.
Sources
- DrugPatentWatch – Bridion (sugammadex)